Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

Recruiting now · Not applicable

Conditions studied: Pertussis, Diphtheria, Tetanus, Haemophilus Influenzae Type B Infection, Polio

In brief

The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.

Key facts

Study ID

NCT06605755

Run by

Jiangsu Province Centers for Disease Control and Prevention

People needed

785

Starts

2024-09-05

Expected to finish

2026-02-01

Last updated by the study team

2024-09-20

Who can join

Age: 2 and older, up to 2. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• (1)Received 4 doses of DTaP-IPV/Hib pentavalent vaccines (2) Obtained consent from the participant's caregiver and sign an informed consent form

You may not qualify if…

• (1) Diagnosed by a physician with a coagulation abnormality (e.g., coagulation factor deficiency, coagulopathy, platelet abnormality) (2) Any other factor considered to make participation in the trial unsuitable.

Where it is running

• Jingsu Provincial Centre of Disease Control and Prevention — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.